J 2024

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

POKRIVČÁK, Tomáš, Jiří NAVRÁTIL, Alexandr POPRACH, Michal STANÍK, Igor KISS et. al.

Basic information

Original name

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Authors

POKRIVČÁK, Tomáš (203 Czech Republic, belonging to the institution), Jiří NAVRÁTIL (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution) and Igor KISS (203 Czech Republic, belonging to the institution)

Edition

CASE REPORTS IN ONCOLOGY, BASEL, KARGER, 2024, 1662-6575

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.800 in 2022

Organization unit

Faculty of Medicine

DOI

UT WoS

001201754100001

Keywords in English

Enzalutamide; Metastatic castration-resistant prostate cancer; Aged 75 and over; Comorbidity

Tags

Tags

International impact, Reviewed
Změněno: 5/6/2024 13:02, Mgr. Tereza Miškechová

Abstract

V originále

Introduction: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. Case Presentation: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. Conclusion: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.